Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial.

Nat Commun · 2026 · PMC13316022 · PMID 42026044

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

An exploratory analysis suggested a numerical trend towards a higher MPR rate in patients with PD-L1 CPS ≥ 20 (57.1%, 4/7, 95%CI: 0.18–0.90) compared to those with CPS < 20 (22.2%, 2/9, 95%CI: 0.03–0.60).

also in 723 other papers

showed a trendno p-value reported

In the first-line CheckMate 649 trial, EBVaGC patients showed a trend toward improved survival with nivolumab plus chemotherapy (HR 0.61, 95% CI 0.26–1.45) or nivolumab plus ipilimumab (HR 0.76, 95% CI 0.22–2.64) compared to chemotherapy alone, although these results were not statistically significant due to the small subgroup size 26 .

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.